摘要
对宁泌泰胶囊治疗泌尿系感染有效性与安全性进行系统评价。整合中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、Cochrane Library、PubMed、EMbase、Web of Science中,自建库至2021年10月的宁泌泰胶囊治疗泌尿系感染相关文献,筛选宁泌泰胶囊治疗泌尿系感染的随机对照试验(RCTs),并采用国际Cochrane协作组提供的ROB工具与RevMan 5.3软件进行数据整合与Meta分析。共纳入17项RCTs,总样本量1972例,试验组1045例,对照组927例。Meta分析结果显示,宁泌泰胶囊+常规抗生素治疗急性肾盂肾炎的临床治愈率(RR=1.94,95%CI[1.58,2.37],P<0.00001)、尿红细胞计数减少程度(MD=-3.22,95%CI[-3.23,-3.21],P<0.00001)、尿白细胞计数减少程度(MD=-2.34,95%CI[-2.59,-2.10],P<0.00001)、急性肾盂肾炎症状消失时间(MD_(尿路刺激消失时间)=-2.19,95%CI[-2.69,-1.68],P<0.00001;MD_(腰酸痛消失时间)=-3.58,95%CI[-4.20,-2.97],P<0.00001;MD_(发热消失时间)=-0.57,95%CI[-0.81,-0.33],P<0.00001)均优于仅使用常规抗生素治疗,且宁泌泰胶囊+头孢菌素类/喹诺酮类均提高了临床治愈率(RR_(联合头孢菌素类)=1.94,95%CI[1.56,2.42],P<0.00001;RR_(联合喹诺酮类)=1.91,95%CI[1.16,3.15],P=0.01);宁泌泰胶囊治疗糖尿病合并泌尿系感染的临床治愈率(RR=1.91,95%CI[1.47,2.49],P<0.00001)优于喹诺酮类药物;宁泌泰胶囊联合常规四环素类与大环内酯类抗生素治疗非淋球菌性尿道炎的临床治愈率(RR=1.22,95%CI[1.09,1.37],P=0.0005)优于仅使用常规抗生素;宁泌泰胶囊联合常规抗生素/单用宁泌泰胶囊治疗泌尿系感染的临床治愈率(RR=1.35,95%CI[1.17,1.56],P<0.0001)、不良反应发生率(RR=0.32,95%CI[0.15,0.68],P=0.003)不高于仅使用常规抗生素治疗,协同治疗时以联合喹诺酮类抗生素效果最好(RR=1.30,95%CI[1.04,1.61],P=0.02)。不良反应主要为轻度胃肠道不适、恶心、呕吐、口干等,均较轻微。基于现有数据分析,宁泌
This study aims to evaluate the effectiveness and safety of Ningmitai Capsules in the treatment of urinary tract infection.To be specific,articles on the treatment of urinary tract infection with Ningmitai Capsules were retrieved from China National Know-ledge Infrastructure(CNKI),Wanfang,VIP,SinoMed,Cochrane Library,PubMed,EMbase,and Web of Science(from establishment to October 2021).Eligible randomized controlled trials(RCTs)were screened out,and ROB and RevMan 5.3 of Cochrane were employed for data integration and Meta-analysis.Finally,17 articles were included,involving 1972 cases,with 1045 in the experimental group and 927 in the control group.The Meta-analysis results are as follows.Ningmitai Capsules combined with conventional antibiotics was superior to sensitive antibiotics alone in the treatment of acute pyelonephritis in aspects of clinical cure rate(RR=1.94,95%CI[1.58,2.37],P<0.00001),reduction in the count of red blood cells in the urine(MD=-3.22,95%CI[-3.23,-3.21],P<0.00001),decrease in the count of white blood cells in the urine(MD=-2.34,95%CI[-2.59,-2.10],P<0.00001),and time for the disappearance of the symptoms(MD_(time for urinary tract irritation disappeared)=-2.19,95%CI[-2.69,-1.68],P<0.00001;MD_(time for waist aches disappeared)=-3.58,95%CI[-4.20,-2.97],P<0.00001;MD_(time for heating disappeared)=-0.57,95%CI[-0.81,-0.33],P<0.00001).The combination of either cephalosporin or quinolone with Ningmitai Capsules can improve clinical cure rate of acute pyelonephritis(RR_(combined with cephalosporin)=1.94,95%CI[1.56,2.42],P<0.00001;RR_(combined with quinolone)=1.91,95%CI[1.16,3.15],P=0.01).The clinical cure rate(RR=1.91,95%CI[1.47,2.49],P<0.00001)of diabetes complicated with urinary tract infection by Ningmitai Capsules was higher than that by quinolones.The clinical cure rate(RR=1.22,95%CI[1.09,1.37],P=0.0005)of non-gonococcal urethritis by Ningmitai Capsules combined with conventional tetracycline and macrolide antibiotics was higher than that by conventional antibiotics.Ningmitai Capsules combine
作者
王自强
吕健
厉将斌
谢雁鸣
WANG Zi-qiang;LYU Jian;LI Jiang-bin;XIE Yan-ming(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Guang′anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Monitoring and Statistical Research Center,National Administration of Traditional Chinese Medicine,Beijing 100027,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2022年第13期3648-3657,共10页
China Journal of Chinese Materia Medica
基金
国家重点研发计划“中医药现代化研究”项目(2018YFC1707400)。
关键词
宁泌泰胶囊
泌尿系感染
随机对照试验
系统评价
META分析
Ningmitai Capsules
urinary tract infection
randomized controlled trial
systematic review
Meta-analysis
